tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Amid Promising MS Trial Results
PremiumRatingsBuy Rating Affirmed for Immunic’s Vidofludimus Calcium Amid Promising MS Trial Results
1M ago
Immunic Presents Promising Phase 2 Trial Results
Premium
Company Announcements
Immunic Presents Promising Phase 2 Trial Results
1M ago
Immunic receives notice of allowance for vidofludimus calcium patent
Premium
The Fly
Immunic receives notice of allowance for vidofludimus calcium patent
2M ago
Immunic announces vidofludimus calcium trial data
PremiumThe FlyImmunic announces vidofludimus calcium trial data
5M ago
Immunic completes enrollment for both ENSURE trials
Premium
The Fly
Immunic completes enrollment for both ENSURE trials
5M ago
Immunic Approves Equity Plan Amendment at Annual Meeting
Premium
Company Announcements
Immunic Approves Equity Plan Amendment at Annual Meeting
5M ago
Immunic announces offering of warrants to purchase common stock
PremiumThe FlyImmunic announces offering of warrants to purchase common stock
5M ago
Immunic price target lowered to $5 from $6 at B. Riley
Premium
The Fly
Immunic price target lowered to $5 from $6 at B. Riley
6M ago
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
Premium
Ratings
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100